CD38-SADA:177 Lu-DOTA Drug Complex

N/A

Report date: 2026/03/13 20:02:36

Base Information

Drug NameCD38-SADA:177 Lu-DOTA Drug Complex

Drug Alias NameCD38-SADA:177Lu-DOTA complex

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionIonising radiation emittersLymphocyte differentiation antigen CD38 modulators

TargetsLymphocyte differentiation antigen CD38

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesY-Mabs Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesY-Mabs Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A